Drug Co-Pay Subsidies From Pharma At Odds With Goals Of Health Reform - Medco
This article was originally published in The Pink Sheet Daily
Executive Summary
From a health care reform perspective, the industry's increasing practice of providing subsidies that help keep patients on higher cost drugs "is a really bad thing to do" and "should not be allowed," Chairman Snow comments during PBM's earnings call.
You may also be interested in...
Can Pharma Industry Afford To Give Up More For Health Reform? PhRMA Calls President "Misinformed"
Pharmaceutical Research and Manufacturers trade group responds to President Obama's claim that the pharmaceutical industry can afford to give up more than the $80 billion previously agreed to.
PhRMA Health Reform Deal Is Not Binding On House, Rep. Waxman Declares
Waxman will keep pushing for Part D rebates to help fund closing the coverage gap, regardless of PhRMA's proposal for a different discount model. The good news for industry is that "dollars for donuts" remains the formula--and that even Waxman thinks industry will end up getting more than it gives.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.